Synapse
⌘+K
Synapse
PulseExploreClubsResearchersJournals
Instagram
HomeClubsExplore
January 1, 2013Thrombosis and Haemostasis

The perioperative management of new direct oral anticoagulants: a question without answers

View Full Paper
Ask AI
Bookmark
Share

Why the study?

How should direct oral anticoagulants be managed perioperatively in patients undergoing elective or emergency surgery?

Population

Patients on direct oral anticoagulants who need elective or emergency surgery

Design

Review

Authors

JAJosé De AndrésApple (Israel)CGC. GomarUniversidad InternacionalAGA. Gómez‐LuqueHospital Clínico Universitario de Valencia

Discussion

Loading...

Member takes

Overview

Perioperative DOAC strategies rely on trends without definitive data; leaves open optimal bridging and rescue approaches pending prospective trials.

Structured PICO

How should direct oral anticoagulants be managed perioperatively in patients undergoing elective or emergency surgery?

P
Population
Patients on direct oral anticoagulants (apixaban, dabigatran, and rivaroxaban) who need elective or emergency surgery
I
Intervention
Perioperative management strategies (stopping DOAC 1-5 days before surgery without bridging vs. stopping 5 days preoperatively and bridging with low-molecular-weight heparin, and rescue treatments for emergency surgery)

This review highlights the lack of definitive data and outlines current trends for managing DOACs in the perioperative setting, including bridging and non-bridging strategies.

Limitations

  • lack of experience and data

Cite This Study

Andrés et al. (2013) studied this question.

synapsesocial.com/papers/6a8219b48ef2ccdd49f251e7https://doi.org/10.1160/th12-11-0868
View Full Paper
Ask AI
Bookmark
Share

Also Consider

Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context:

  1. 1How I treat with anticoagulants in 2012: new and old anticoagulants, and when and how to switch2012 · 248 citations
  2. 2Oral dabigatran versus enoxaparin for thromboprophylaxis after primary total hip arthroplasty (RE-NOVATE II)2011 · 402 citations
  3. 3Dabigatran Etexilate: An Oral Direct Thrombin Inhibitor for Prophylaxis and Treatment of Thromboembolic Diseases2008 · 109 citations
  4. 4Periprocedural Bleeding and Thromboembolic Events With Dabigatran Compared With Warfarin2012 · 542 citations
  5. 5Dabigatran etexilate – a novel, reversible, oral direct thrombin inhibitor: Interpretation of coagulation assays and reversal of anticoagulant activity2010 · 1,381 citations